CA2365636A1 - Ligand multifonctionnel - Google Patents

Ligand multifonctionnel Download PDF

Info

Publication number
CA2365636A1
CA2365636A1 CA002365636A CA2365636A CA2365636A1 CA 2365636 A1 CA2365636 A1 CA 2365636A1 CA 002365636 A CA002365636 A CA 002365636A CA 2365636 A CA2365636 A CA 2365636A CA 2365636 A1 CA2365636 A1 CA 2365636A1
Authority
CA
Canada
Prior art keywords
ligand
antibody
cell
cells
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002365636A
Other languages
English (en)
Inventor
William Herman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002365636A priority Critical patent/CA2365636A1/fr
Publication of CA2365636A1 publication Critical patent/CA2365636A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA002365636A 2001-12-05 2001-12-05 Ligand multifonctionnel Abandoned CA2365636A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002365636A CA2365636A1 (fr) 2001-12-05 2001-12-05 Ligand multifonctionnel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002365636A CA2365636A1 (fr) 2001-12-05 2001-12-05 Ligand multifonctionnel

Publications (1)

Publication Number Publication Date
CA2365636A1 true CA2365636A1 (fr) 2003-06-05

Family

ID=4170896

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002365636A Abandoned CA2365636A1 (fr) 2001-12-05 2001-12-05 Ligand multifonctionnel

Country Status (1)

Country Link
CA (1) CA2365636A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110824173A (zh) * 2019-11-27 2020-02-21 中国人民解放军陆军军医大学第一附属医院 促血管生成因子pdgfc在作为诊断和治疗肝肺综合征的标志物中的应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110824173A (zh) * 2019-11-27 2020-02-21 中国人民解放军陆军军医大学第一附属医院 促血管生成因子pdgfc在作为诊断和治疗肝肺综合征的标志物中的应用
CN110824173B (zh) * 2019-11-27 2022-09-02 中国人民解放军陆军军医大学第一附属医院 促血管生成因子pdgfc在作为诊断和治疗肝肺综合征的标志物中的应用

Similar Documents

Publication Publication Date Title
Labrijn et al. Bispecific antibodies: a mechanistic review of the pipeline
Kholodenko et al. Antibody fragments as potential biopharmaceuticals for cancer therapy: success and limitations
Sandhu Protein engineering of antibodies
Morrison In vitro antibodies: strategies for production and application
US20090104195A1 (en) Targeted ligands
KR102749049B1 (ko) 분자를 표적화하기 위한 항원 결합 구조체
US6551592B2 (en) Bi-and trispecific antibodies for the induction of anti-tumor immunity
KR101287777B1 (ko) 가용성 ｃｅａ에 대한 내성을 가지는 약학적 조성물
EP3442567B1 (fr) Anticorps anti-psma et leur utilisation
US20220323600A1 (en) Teac and attac immunooncology compositions and methods
US20050069549A1 (en) Targeted ligands
CN110621337A (zh) 抗lag3人单克隆抗体及其用途
JP2020529864A (ja) 多重特異性抗体とその作製及び使用方法
CA3206603A1 (fr) Anticorps anti-cd3 et procedes d'utilisation associes
CZ20023203A3 (cs) Multifunkční polypeptidy obsahující vazebné místo k epitopu receptorového komplexu NKG2D
US20160297881A1 (en) BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1
Müller et al. Bispecific Antibodies
JP2020530777A (ja) 多重特異性抗体とその作製及び使用方法
CA2401252A1 (fr) Anticorps humains specifiques de fap-.alpha.
Nieri et al. Antibodies for therapeutic uses and the evolution of biotechniques
Acheampong Bispecific antibody (bsAb) construct formats and their application in cancer therapy
Stamova et al. Unexpected recombinations in single chain bispecific anti-CD3–anti-CD33 antibodies can be avoided by a novel linker module
Müller et al. Bispecific antibodies
CA2414148A1 (fr) Ligands cibles
US20250051440A1 (en) Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling

Legal Events

Date Code Title Description
FZDE Dead